دورية أكاديمية
Single nucleotide variants in the CCL2 , OAS1 and DPP9 genes and their association with the severity of COVID-19 in an Ecuadorian population.
| العنوان: | Single nucleotide variants in the CCL2 , OAS1 and DPP9 genes and their association with the severity of COVID-19 in an Ecuadorian population. |
|---|---|
| المؤلفون: | Chávez-Vélez E; Carrera de Biología, Facultad de Ciencias Biológicas, Universidad Central del Ecuador, Quito, Ecuador., Álvarez-Nava F; Carrera de Biología, Facultad de Ciencias Biológicas, Universidad Central del Ecuador, Quito, Ecuador., Torres-Vinueza A; Carrera de Biología, Facultad de Ciencias Biológicas, Universidad Central del Ecuador, Quito, Ecuador., Balarezo-Díaz T; Carrera de Biología, Facultad de Ciencias Biológicas, Universidad Central del Ecuador, Quito, Ecuador., Pilataxi K; Carrera de Biología, Facultad de Ciencias Biológicas, Universidad Central del Ecuador, Quito, Ecuador., Acosta-López C; Carrera de Biología, Facultad de Ciencias Biológicas, Universidad Central del Ecuador, Quito, Ecuador., Peña IZ; Unidad de Cuidados Críticos de Adultos, Hospital Quito Sur del Instituto Ecuatoriano de Securidad Social, Quito, Ecuador., Narváez K; Unidad de Cuidados Críticos de Adultos, Hospital Quito Sur del Instituto Ecuatoriano de Securidad Social, Quito, Ecuador. |
| المصدر: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 Apr 17; Vol. 14, pp. 1322882. Date of Electronic Publication: 2024 Apr 17 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media SA |
| مواضيع طبية MeSH: | Polymorphism, Single Nucleotide* , 2',5'-Oligoadenylate Synthetase*/genetics , COVID-19*/genetics , Chemokine CCL2*/genetics , Severity of Illness Index* , SARS-CoV-2*/genetics, Humans ; Ecuador/epidemiology ; Female ; Male ; Case-Control Studies ; Adult ; Middle Aged ; Genetic Predisposition to Disease ; Genotype ; Gene Frequency ; Aged ; Young Adult |
| مستخلص: | COVID-19 has a broad clinical spectrum, ranging from asymptomatic-mild form to severe phenotype. The severity of COVID-19 is a complex trait influenced by various genetic and environmental factors. Ethnic differences have been observed in relation to COVID-19 severity during the pandemic. It is currently unknown whether genetic variations may contribute to the increased risk of severity observed in Latin-American individuals The aim of this study is to investigate the potential correlation between gene variants at CCL2 , OAS1 , and DPP9 genes and the severity of COVID-19 in a population from Quito, Ecuador. This observational case-control study was conducted at the Carrera de Biologia from the Universidad Central del Ecuador and the Hospital Quito Sur of the Instituto Ecuatoriano de Seguridad Social (Quito-SUR-IESS), Quito, Ecuador. Genotyping for gene variants at rs1024611 (A>G), rs10774671 (A>G), and rs10406145 (G>C) of CCL2 , OAS1 , and DPP9 genes was performed on 100 COVID-19 patients (43 with severe form and 57 asymptomatic-mild) using RFLP-PCR. The genotype distribution of all SNVs throughout the entire sample of 100 individuals showed Hardy Weinberg equilibrium ( P =0.53, 0.35, and 0.4 for CCL2 , OAS1 , and DPP9 , respectively). The HWE test did not find any statistically significant difference in genotype distribution between the study and control groups for any of the three SNVs. The multivariable logistic regression analysis showed that individuals with the GG of the CCL2 rs1024611 gene variant had an increased association with the severe COVID-19 phenotype in a recessive model ( P = 0.0003, OR = 6.43, 95% CI 2.19-18.89) and for the OAS1 rs10774671 gene variant, the log-additive model showed a significant association with the severe phenotype of COVID-19 ( P =0.0084, OR=3.85, 95% CI 1.33-11.12). Analysis of haplotype frequencies revealed that the coexistence of GAG at CCL2 , OAS1 , and DPP9 variants, respectively, in the same individual increased the presence of the severe COVID-19 phenotype (OR=2.273, 95% CI: 1.271-4.068, P =0.005305). The findings of the current study suggests that the ethnic background affects the allele and genotype frequencies of genes associated with the severity of COVID-19. The experience with COVID-19 has provided an opportunity to identify an ethnicity-based approach to recognize genetically high-risk individuals in different populations for emerging diseases. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Chávez-Vélez, Álvarez-Nava, Torres-Vinueza, Balarezo-Díaz, Pilataxi, Acosta-López, Peña and Narváez.) |
| References: | Nat Genet. 2021 Nov;53(11):1606-1615. (PMID: 34737427) Immunobiology. 2024 Mar;229(2):152789. (PMID: 38290406) Nature. 2022 Aug;608(7923):593-602. (PMID: 35714668) Twin Res Hum Genet. 2020 Dec;23(6):316-321. (PMID: 33558003) Science. 2022 May 6;376(6593):eabn4947. (PMID: 35289632) Lancet. 2021 May 8;397(10286):1711-1724. (PMID: 33939953) Sci Rep. 2022 Jan 28;12(1):1554. (PMID: 35091640) J Med Virol. 2022 Jul;94(7):2969-2976. (PMID: 35246846) Allergy. 2021 Feb;76(2):428-455. (PMID: 33185910) Front Immunol. 2021 Apr 01;12:622176. (PMID: 33868239) Circulation. 2005 Aug 23;112(8):1113-20. (PMID: 16116069) JAMA. 2020 Jun 23;323(24):2466-2467. (PMID: 32391864) Gastroenterology. 2003 Oct;125(4):1085-93. (PMID: 14517792) Lancet Glob Health. 2022 Jul;10(7):e961-e969. (PMID: 35597249) Mucosal Immunol. 2013 Jan;6(1):45-55. (PMID: 22692455) J Med Virol. 2020 Jun;92(6):568-576. (PMID: 32134116) BMC Cell Biol. 2014 Sep 09;15:33. (PMID: 25205466) Nature. 2021 Apr;592(7856):778-783. (PMID: 33731932) Lancet. 2022 Apr 16;399(10334):1489-1512. (PMID: 35120592) N Engl J Med. 2022 Jun 2;386(22):2140-2142. (PMID: 35507476) Nat Rev Microbiol. 2021 Jul;19(7):409-424. (PMID: 34075212) HGG Adv. 2021 Aug 20;2(4):100050. (PMID: 35047841) Gene. 2022 Aug 20;836:146674. (PMID: 35714803) Front Cell Infect Microbiol. 2022 Sep 09;12:951383. (PMID: 36164552) Nat Genet. 2022 Apr;54(4):382-392. (PMID: 35241825) Meta Gene. 2015 May 22;5:1-8. (PMID: 26042205) Sci Rep. 2021 May 12;11(1):10066. (PMID: 33980912) J Racial Ethn Health Disparities. 2022 Dec;9(6):2334-2339. (PMID: 34647273) Genome Med. 2021 May 17;13(1):83. (PMID: 34001247) Forensic Sci Int Genet. 2017 Nov;31:29-33. (PMID: 28826061) Nat Rev Genet. 2022 Sep;23(9):533-546. (PMID: 35501396) Nature. 2022 Feb;602(7898):654-656. (PMID: 35016196) Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13795-800. (PMID: 12374865) Medicine (Baltimore). 2022 Aug 12;101(32):e29903. (PMID: 35960063) Postgrad Med J. 2008 Sep;84(995):498-501. (PMID: 18940951) J Exp Med. 2005 Dec 19;202(12):1649-58. (PMID: 16352737) PLoS One. 2012;7(2):e32275. (PMID: 22384203) Nature. 2022 Jun;606(7914):585-593. (PMID: 35483404) Nat Commun. 2017 Feb 27;8:14357. (PMID: 28240269) Nature. 2021 Mar;591(7848):92-98. (PMID: 33307546) Hum Immunol. 2013 Mar;74(3):395-401. (PMID: 23220500) Lancet. 2022 Jan 29;399(10323):437-446. (PMID: 35065011) Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463) J Clin Invest. 2021 Dec 1;131(23):. (PMID: 34597274) Am J Hum Genet. 2005 Apr;76(4):623-33. (PMID: 15732009) Sci Rep. 2019 Dec 27;9(1):19889. (PMID: 31882771) Heredity (Edinb). 2016 Jun;116(6):558-68. (PMID: 27071844) Nat Commun. 2021 Jul 27;12(1):4569. (PMID: 34315903) Hum Immunol. 2001 Sep;62(9):1001-8. (PMID: 11543902) J Occup Environ Med. 2021 Apr 1;63(4):291-295. (PMID: 33315723) BMC Med. 2020 May 29;18(1):160. (PMID: 32466757) Lancet Infect Dis. 2022 Jul;22(7):959-966. (PMID: 35468332) Front Med (Lausanne). 2020 Oct 30;7:582793. (PMID: 33195331) Intervirology. 2020 Dec 9;:1-12. (PMID: 33296901) Am J Pathol. 2022 Apr;192(4):642-652. (PMID: 35123975) Int J Mol Epidemiol Genet. 2021 Jun 15;12(3):52-60. (PMID: 34336138) J Hum Genet. 2013 Jun;58(6):362-5. (PMID: 23575436) Int J Infect Dis. 2022 Sep;122:427-436. (PMID: 35753602) Genome Med. 2020 Jul 8;12(1):60. (PMID: 32641083) Nature. 2022 Mar;603(7902):687-692. (PMID: 35062015) J Infect. 2015 Jul;71(1):101-9. (PMID: 25818534) Lancet. 2021 Dec 11;398(10317):2126-2128. (PMID: 34871545) Nature. 2022 Mar;603(7902):715-720. (PMID: 35104836) Nat Genet. 2021 Jun;53(6):801-808. (PMID: 33888907) Genes Immun. 2012 Dec;13(8):605-20. (PMID: 22992722) EBioMedicine. 2021 Oct;72:103629. (PMID: 34655949) |
| فهرسة مساهمة: | Keywords: CCL2; COVID-19; DPP9; Hardy-Weinberg equilibrium; OAS1; SNV; association genetic study; gene variant |
| المشرفين على المادة: | EC 2.7.7.84 (2',5'-Oligoadenylate Synthetase) EC 2.7.7.- (OAS1 protein, human) 0 (Chemokine CCL2) 0 (CCL2 protein, human) |
| تواريخ الأحداث: | Date Created: 20240502 Date Completed: 20240502 Latest Revision: 20240614 |
| رمز التحديث: | 20240615 |
| مُعرف محوري في PubMed: | PMC11061356 |
| DOI: | 10.3389/fcimb.2024.1322882 |
| PMID: | 38694517 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2235-2988 |
|---|---|
| DOI: | 10.3389/fcimb.2024.1322882 |